NFKB1 and acute liver failure: Wu et al. demonstrated that oral administration of baicalein can improve D-galactosamine or lipopolysaccharide or CCl4-induced acute liver failure and liver fibrosis by blocking the recruitment of NF-κB signaling [42,61,62].